Intuitive Surgical, Inc.
Intuitive Surgical Completes Acquisition of da Vinci and Ion Distribution Business in Europe
Summary
On March 2, 2026, Intuitive Surgical, Inc. announced the completion of its acquisition of the da Vinci and Ion distribution business from ab medica, Abex, Excelencia Robótica, and their affiliates. This acquisition marks the expansion of Intuitive's direct operations in Europe, enabling the company to better support customers in Italy, Spain, Portugal, Malta, San Marino, and associated territories. The acquisition is expected to improve patient outcomes, patient and care team experience, access to minimally invasive care, and lower the total cost of care. The business operations are now integrated into Intuitive's European commercial and marketing organization.
Profitelligence Alerts
Get alerts for ISRG
Be first to know when Intuitive Surgical, Inc. files with the SEC.
Filing Categories
Advertisement
About Intuitive Surgical, Inc.
Intuitive Surgical, Inc. is a pioneering company in the field of robotic-assisted, minimally invasive surgery. It is renowned for its development of the da Vinci Surgical System, which revolutionizes surgical procedures by enhancing precision, flexibility, and control beyond the physical capabilities of the human hand. The company's cornerstone product allows surgeons to perform complex surgeries through small incisions, which can lead to quicker patient recovery, reduced hospital stays, and lower complication rates. Operating predominantly in the healthcare sector, Intuitive Surgical serves a significant role in advancing surgical technology and improving patient outcomes. The company collaborates across diverse medical specialties, including urology, gynecology, and general surgery, to expand the applications and accessibility of its robust surgical systems. As an innovator in the medical device industry, Intuitive Surgical has a profound impact not only on surgical methodologies but also on the economic aspects of medical practices by potentially lowering surgical costs. It continues to shape the future of surgery with its commitment to enhancing robotic-assisted techniques.
Official SEC Documents
Advertisement